Navigation Links
$37 million financing for company based on macular degeneration research
Date:10/9/2007

New Haven, Conn. Optherion, Inc. a company that will use groundbreaking discoveries by scientists at Yale and the University of Iowa to develop products to diagnose and treat Age-related Macular Degeneration (AMD) and other related chronic diseases has received $37 million in start-up financing.

Discoveries in 2005 by Josephine Hoh at Yale School of Public Health and Gregory Hageman at the University of Iowa linked Complement Factor H (CFH) and Complement Factor B (CFB) two elements of the alternate complement pathway of the immune system with AMD. These factors are involved in inflammatory responses, which can cause tissue damage when improperly controlled.

AMD is caused by degeneration of the macula, the region of the retina responsible for central vision. There are two forms of AMD, dry and wet. AMD is the leading cause of blindness in people over age 60 in the developed world. Dry AMD is the most common form, while wet AMD is a less prevalent and more aggressive form of the disease with growth of new blood vessels into the retina.

Optherions initial focus will be to develop disease-modifying therapies to prevent loss of vision in patients with dry AMD, as well as a portfolio of tests that predict, diagnose and monitor progression of the disease.

AMD is unusual because it is a widespread disease that is caused by common variations in only a few specific genes. Approximately 50% of patients with AMD suffer from variations in the CFH gene, and 74% of the disease can be explained by variations in the CFH and CFB genes combined. Variants in other genes, found on Chromosome 10, are also implicated in AMD, and will be a further focus for the companys development of therapeutic and diagnostic products.

In the future, the companys proprietary technologies will also be extended to the possible diagnosis and treatment of other chronic diseases related to the alternative complement system.

We are extraordinarily pleased to have these discoveries so rapidly and substantially supported as they are translated into valuable diagnostics, said John Puziss, Director of Technology Licensing for Yales Office of Cooperative Research. We also want to thank the Sackler Fund for the Arts and Sciences and Raymond and Beverly Sackler, long standing supporters of medical research and the Yale School of Medicine, for the grant that funded this landmark research and the Verto Institute founded and directed by Jonathan and Richard Sackler that continues to fund Dr. Hohs projects in ophthalmology and other diseases.

Colin J. Foster, Optherions President and CEO, said, We are embarking on a program that exploits a new and exciting area of research with breakthrough potential in areas of high unmet medical need. Foster is the former CEO of Bayer Pharmaceuticals in the U.S. and Region Head for Bayer Pharmaceuticals in North America.

Among the sources of capital for the financing are: Quaker BioVentures, Philadelphia; Domain Associates, Princeton, NJ and San Diego; Johnson & Johnson Development Corporation, New Brunswick, NJ; Purdue Pharmaceutical Products L.P., Stamford, CT; Pappas Ventures, Research Triangle Park, NC; Biogen Idec New Ventures, Cambridge, MA and GE Healthcare Financial Services, Chicago, IL.

The successful completion of this Series A financing will enable the company to advance the work of Dr. Hageman, Dr. Hoh and others, and hopefully transform the diagnosis and treatment of dry age-related macular degeneration, said David Scheer, Chairman of the Optherion Board of Directors.


'/>"/>

Contact: Janet Rettig Emanuel
janet.emanuel@yale.edu
203-432-2157
Yale University
Source:Eurekalert

Related medicine news :

1. Drug May Make Breathing Easier for Millions
2. Hundred million dollar gift for malaria institute
3. George Bush pledges 200 million dollars for AIDS relief
4. Hope for 11 million children facing death from illnesses
5. The forgotten epidemic killing millions
6. WHO and UNAIDS unveil plan to get 3 million AIDS patients on treatment by 2005
7. Over Six Million HIV Infected People In South Africa- Finds A Survey
8. Tanzanian Government Sanctions $20 Million For AIDS Arug
9. Grant of $7 million for Orissa Medical College from Japan
10. Merck to pay $ 253.5 million to Vioxx victim family
11. GlaxoSmithKline to Supply United States with 8 Million flu vaccine, Fluarix
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... Yardley, PA (PRWEB) , ... March 23, 2017 ... ... received Patient Oriented Disease Management Accreditation from the NCQA. The accreditation covers StayWell’s ... programs. , Accredited status is granted to organizations that have excellent programs ...
(Date:3/23/2017)... ... , ... The TouchPoint Solution, home of Buzzies *, is boosting the ... , “Buzzies change the way we interact with stress and live our day-to-day lives,” ... date in December 2016, The TouchPoint Solution has sold more than $750,000 in product ...
(Date:3/23/2017)... , ... March 23, 2017 , ... After raising more ... FaceCradle , the most-funded travel pillow in crowdfunding history, has established a ... its wildly popular travel innovation to Americans. , “We’re excited to be operating on ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... today announced rapid completion of the strategic executive team expansion needed to further ... to the ChenMed executive team,” says Christopher Chen, MD, ChenMed Chief Executive Officer. ...
(Date:3/23/2017)... ... March 23, 2017 , ... Natural Subsistence, ... aspects of people’s health and nutrition, announced its product Leyzene is now available ... Subsistence develops nutritional supplements that help people improve all aspects of their health ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... MUMBAI , March 23, 2017 ... de Piramal Enterprises Limited, anuncia el nombramiento de ... PPS ofrece una plataforma de servicios integrados completa ... Needleman desempeñará un cargo clave en el crecimiento ... comercial, Needleman será responsable de impulsar todas las ...
(Date:3/23/2017)... 23, 2017  Galmed Pharmaceuticals Ltd. (Nasdaq: ... clinical-stage biopharmaceutical company focused on the development of ... nonalcoholic steatohepatitis, or NASH, and other liver diseases, ... twelve months ended December 31, 2016, and announced new ... demonstrating Aramchol™,s potential direct effect on liver fibrosis. ...
(Date:3/23/2017)... 23, 2017 ReNeuron reported in December ... in chronic stroke patients, despite not meeting the three-month time ... the Action Research Arm Test (ARAT). As a result, the ... controlled clinical study in 2017. Beyond CTX, we expect safety ... 2017 and Phase I data from its critical limb ischaemia ...
Breaking Medicine Technology: